(Q87227213)
Statements
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma (English)
Lei Liu
Weijuan Wang
Hui Chen
Yan Zhao
Wei Bai
Zhanxin Yin
Chuangye He
Jia Jia
Man Yang
Jielai Xia
Daiming Fan